KYMR Kymera Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KYMR

Price (delayed)

$74.71

Market cap

$6.15B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.58

Enterprise value

$6.08B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 32

Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein ...

Highlights
Kymera Therapeutics's quick ratio has increased by 32% YoY and by 2.1% QoQ
KYMR's debt is down by 7% year-on-year and by 2.2% since the previous quarter
The equity has soared by 96% YoY but it has contracted by 2.5% from the previous quarter
KYMR's revenue is up by 31% from the previous quarter but it is down by 13% YoY
KYMR's net income is down by 31% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kymeratx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of KYMR

KYMR stock price

How has the Kymera Therapeutics stock price performed over time
Intraday
2.05%
1 week
-8.29%
1 month
-10.62%
1 year
68.8%
YTD
-3.98%
QTD
-10.3%

Financial performance

How have Kymera Therapeutics's revenue and profit performed over time
Revenue
$51.48M
Gross profit
$51.48M
Operating income
-$359.13M
Net income
-$315M
Gross margin
100%
Net margin
-612%
KYMR's net margin is down by 50% year-on-year but it is up by 23% since the previous quarter
The operating margin has contracted by 48% YoY but it has grown by 22% from the previous quarter
KYMR's revenue is up by 31% from the previous quarter but it is down by 13% YoY
KYMR's net income is down by 31% year-on-year

Price vs fundamentals

How does KYMR's price correlate with its fundamentals

Growth

What is Kymera Therapeutics's growth rate over time

Valuation

What is Kymera Therapeutics stock price valuation
P/E
N/A
P/B
3.96
P/S
141.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
118.04
The company's EPS fell by 15% YoY but it rose by 3% QoQ
The equity has soared by 96% YoY but it has contracted by 2.5% from the previous quarter
The stock's price to book (P/B) is 2.1% more than its 5-year quarterly average of 3.8 and 2.1% more than its last 4 quarters average of 3.8
The price to sales (P/S) is 166% higher than the 5-year quarterly average of 52.2 and 7% higher than the last 4 quarters average of 129.2
KYMR's revenue is up by 31% from the previous quarter but it is down by 13% YoY

Efficiency

How efficient is Kymera Therapeutics business performance
The company's return on sales fell by 50% YoY but it rose by 23% QoQ
The company's return on equity rose by 17% YoY and by 14% QoQ
The return on invested capital has grown by 14% since the previous quarter and by 4.3% year-on-year
KYMR's return on assets is up by 13% year-on-year and by 12% since the previous quarter

Dividends

What is KYMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KYMR.

Financial health

How did Kymera Therapeutics financials performed over time
The total assets has soared by 82% YoY but it has contracted by 4.2% from the previous quarter
Kymera Therapeutics's quick ratio has increased by 32% YoY and by 2.1% QoQ
KYMR's debt is 95% smaller than its equity
The equity has soared by 96% YoY but it has contracted by 2.5% from the previous quarter
Kymera Therapeutics's debt to equity has plunged by 55% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.